DDInter704 DDInter1293
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nilotinib
Everolimus {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) is bound by {v} (Compound) Nilotinib
Everolimus {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Everolimus {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Nilotinib
Everolimus {u} (Compound) upregulates {v} (Gene) BNIP3
BNIP3 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Everolimus {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Everolimus {u} (Compound) causes {v} (Side Effect) Lymphopenia
Lymphopenia {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Everolimus {u} (Compound) upregulates {v} (Gene) LYN
LYN {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Everolimus (Compound) upregulates KIT (Gene) and KIT (Gene) is bound by Nilotinib (Compound)
Everolimus (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Nilotinib (Compound)
Everolimus (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Nilotinib (Compound)
Everolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Nilotinib (Compound)
Everolimus (Compound) upregulates BNIP3 (Gene) and BNIP3 (Gene) is downregulated by Nilotinib (Compound)
Everolimus (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Everolimus (Compound) causes Lymphopenia (Side Effect) and Lymphopenia (Side Effect) is caused by Nilotinib (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Everolimus (Compound) upregulates LYN (Gene) and LYN (Gene) is bound by Nilotinib (Compound) and LYN (Gene) is upregulated by Nilotinib (Compound)